Alexander Kai Thomsen

Alexander Kai Thomsen serves as an Assistant Lecturer in the Department of Biomedical Sciences at the University of Copenhagen's Faculty of Health and Medical Sciences, where he combines teaching responsibilities with active research in ophthalmic immunology. His work primarily addresses clinical challenges in neovascular age-related macular degeneration (AMD) treatment.

Thomsen's research focuses on identifying predictive biomarkers for AMD treatment response through immunological and genetic investigations. Key areas include neutrophil-to-lymphocyte ratios, chemokine system dynamics, complement protein pathways, and cytokine-related genetic polymorphisms. His studies examine how these factors influence anti-VEGF therapy outcomes and disease progression, with additional work assessing real-world disruptions like pandemic-related treatment interruptions.

Analysis of his 2024-2025 publications reveals a cohesive research trajectory centered on personalized medicine approaches for AMD. His work consistently links immune cell profiling (neutrophils, T cells), inflammatory markers (interferon-gamma, interleukin-8), and molecular pathways to clinical outcomes, demonstrating translational potential for optimizing treatment regimens and predicting patient responses through accessible biomarkers.